Необязательная аналитика продукта
С вашего разрешения мы используем ограниченную аналитику с защитой конфиденциальности, чтобы понять, какие исследовательские сценарии работают. Мы не используем рекламные трекеры или запись сеансов. Этот выбор можно изменить в настройках. Прочитайте Политику конфиденциальности.
GE HealthCare Technologies Inc.'s published Hold conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $29.2B | |
|---|---|---|
| Revenue (ttm) | 21.6B | |
| Net income (ttm) | 2.2B | |
| EPS (ttm) | $4.73 | |
| Shares out | 451.7M | |
| P/E (trailing) | 16.0x | |
| P/E (forward) | 12.1x | |
| Dividend | $0.16 (0.21%) | |
| Volume | 8,089,827 | |
| Beta | 0.85 |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $17.59B | $18.34B | $19.55B | $19.67B | $20.63B | +4.1% |
| Gross profit | $7.17B | $7.18B | $7.92B | $8.21B | $8.25B | +3.5% |
| Operating income | $2.80B | $2.52B | $2.44B | $2.63B | $2.76B | -0.3% |
| Net income | $2.25B | $1.92B | $1.57B | $1.99B | $2.08B | -1.9% |
| EPS (diluted) | $4.95 | $4.22 | $3.03 | $4.34 | $4.55 | -2.1% |
| EBITDA | $3.54B | $3.17B | $2.44B | $3.67B | $3.79B | +1.7% |
| R&D | $816.0M | $1.03B | $1.21B | $1.31B | $1.26B | +11.5% |
| SG&A | $3.56B | $3.63B | $4.28B | $4.27B | $4.23B | +4.4% |
Recent company headlines from major financial publishers.
The Base scenario projects a target of $68.29 with an assigned probability of 60.0%, representing an expected return of 6.2% relative to $64.29 (as of 2026-10-02). This path requires steady execution across core diagnostic imaging replacement cycles, durable recurring service revenues, and gradual operating margin expansion from standalone supply chain efficiencies. The scenario would be disconfirmed if hospital equipment procurement decelerates into contraction or if pricing concessions in international markets impair gross margin stability. Investors will be able to verify this trajectory through book-to-bill ratios and quarterly imaging segment growth across upcoming reporting periods.
The Bull scenario projects a target of $81.12 with an assigned probability of 20.0%, offering an implied return of 26.2% compared to $64.29 (as of 2026-10-02). Realizing this potential value path requires accelerated hospital fleet modernization driven by artificial intelligence integration, robust post-spin supply chain rationalization, and a sharp rebound in public healthcare procurement across emerging markets. This thesis would be falsified if customer adoption of new digital features stalls or if hospital capital budget constraints cap equipment pricing. Investors will assess progress through sequential order momentum and margin leverage across upcoming fiscal quarters.
| Ke ↓ / g → | 2.0% | 2.3% | 2.5% | 2.8% | 3.0% |
|---|---|---|---|---|---|
| 7.9% | $73.9 | $75.8 | $77.8 | $80.1 | $82.6 |
| 8.4% | $69.4 | $71.0 | $72.7 | $74.5 | $76.5 |
| 8.9% | $65.6 | $66.9 | $68.3 | $69.8 | $71.4 |
| 9.4% | $62.3 | $63.4 | $64.6 | $65.8 | $67.2 |
| 9.9% | $59.4 | $60.3 | $61.3 | $62.4 | $63.5 |
Upcoming earnings date and setup when available.
Рейтинг, который имело опубликованное в каждом месяце издание исследования. Рейтинг сравнивает цену на дату анализа со справедливой стоимостью; он не показывает, оправдалась ли оценка.
| Год | янв. | февр. | март | апр. | май | июнь | июль | авг. | сент. | окт. | нояб. | дек. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
